These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 15207426

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE, Epifanio A, Antonini A, Stocchi F, Martino G, Di Blasi L, Tetto A, Basile G, Imbesi D, La Spina P, Di Raimondo G, Morgante L.
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [Abstract] [Full Text] [Related]

  • 3. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease.
    Alegret M, Valldeoriola F, Martí M, Pilleri M, Junqué C, Rumià J, Tolosa E.
    Mov Disord; 2004 Dec; 19(12):1463-9. PubMed ID: 15390065
    [Abstract] [Full Text] [Related]

  • 4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S, Tings T, Helmschmied K, Neubert K, Wuttke W, Paulus W, Trenkwalder C.
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [Abstract] [Full Text] [Related]

  • 7. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B, Mateo D, Giménez-Roldán S.
    Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
    [Abstract] [Full Text] [Related]

  • 8. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 9. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H.
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [Abstract] [Full Text] [Related]

  • 10. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J.
    Rev Neurol (Paris); 1990 May; 146(2):116-22. PubMed ID: 2320817
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
    García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, Arbelo González J, Baiges Octavio J, Burguera Hernández JA, Calopa Garriga M, Campos Blanco D, Castaño García B, Carballo Cordero M, Chacón Peña J, Espino Ibáñez A, Gorospe Onisalde A, Giménez-Roldán S, Granés Ibáñez P, Hernández Vara J, Ibáñez Alonso R, Jiménez Jiménez FJ, Krupinski J, Kulisevsky Bojarsky J, Legarda Ramírez I, Lezcano García E, Martínez-Castrillo JC, Mateo González D, Miquel Rodríguez F, Mir P, Muñoz Fargas E, Obeso Inchausti J, Olivares Romero J, Olivé Plana J, Otermin Vallejo P, Pascual Sedano B, Pérez de Colosía Rama V, Pérez López-Fraile I, Planas Comes A, Puente Periz V, Rodríguez Oroz MC, Sevillano García D, Solís Pérez P, Suárez Muñoz J, Vaamonde Gamo J, Valero Merino C, Valldeoriola Serra F, Velázquez Pérez JM, Yáñez Baña R, Zamarbide Capdepon I.
    Mov Disord; 2008 Jun 15; 23(8):1130-6. PubMed ID: 18442107
    [Abstract] [Full Text] [Related]

  • 12. The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.
    Vaamonde J, Flores JM, Weisser R, Ibañez R, Obeso JA.
    Mov Disord; 2009 Apr 15; 24(5):762-5. PubMed ID: 19224589
    [Abstract] [Full Text] [Related]

  • 13. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J, Merims D, Kuritzky A, Ziv I, Melamed E.
    Harefuah; 1999 Nov 15; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [Abstract] [Full Text] [Related]

  • 14. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F, Deffond D, Eschalier A, Tournilhac M.
    Rev Neurol (Paris); 1992 Nov 15; 148(10):610-4. PubMed ID: 1295055
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T, Postma AG, Drent M.
    Parkinsonism Relat Disord; 2010 Jan 15; 16(1):71-2. PubMed ID: 19524477
    [No Abstract] [Full Text] [Related]

  • 17. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J, Luquin MR, Obeso JA.
    Mov Disord; 1990 Jan 15; 5(3):260-2. PubMed ID: 2388647
    [Abstract] [Full Text] [Related]

  • 18. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ, Kulisevsky J.
    Rev Neurol; 2012 Jan 15; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stern GM.
    Mov Disord; 1993 Apr 15; 8(2):165-70. PubMed ID: 8474483
    [Abstract] [Full Text] [Related]

  • 20. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L, Albani G, Calderoni S, Baudo S, Lopiano L, Rizzone M, Astolfi V, Cavalli R, Gasco MR, Fraschini F, Bergamasco B, Mauro A.
    Neurol Sci; 2002 Sep 15; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.